Recalls for Lupin contraceptive, Anapen injector; Warning letter for German B.M.P. Bulk Medicines;

> Indian drugmaker Lupin is recalling 10,800 pouches of a contraceptive manufactured in India but distributed throughout the U.S., after a three-month stability test found impurities. Story.

> The FDA has ordered API maker B.M.P. Bulk Medicines & Pharmaceuticals in Norderstedt, Germany, to cease making its ingredients until it decontaminates its plant and changes production processes after inspectors found it was using a shared facility, equipment and dust collection hood on two different products. Warning letter

> Girindus has struck a deal to manufacture and supply certain oligonucleotide constructs using Marina Biotech's conformationally restricted nucleotide (CRN) chemistry. Item

> The Anapen injector, used by people with allergies to treat anaphylactic shock, has been voluntarily recalled in the U.K. by license holder Lincoln Medical because it may not provide the right dose. Notice

> Laboratory equipment maker Thermo Fisher Scientific ($TMO) expects emerging markets like Russia and Brazil to fund its revenue growth as it has in China and India where sales to new pharmaceutical manufacturers and others has added to the bottom line. Story

> The European Directorate for the Quality of Medicines and Healthcare (EDQM) is warning any drug manufacturers that have certificates of suitability to be aware of a scam asking holders to pay €2,000 ($2,517) for inclusion in a directory. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.